Next Article in Journal
Fluoroscopy-Guided Motion Management in Particle Therapy: Evolution, Challenges, and AI-Enabled Opportunities
Next Article in Special Issue
Beyond Angiography: Cardiac CT for Planning Complex PCI in Calcified Coronary Lesions
Previous Article in Journal / Special Issue
Conditional Diffusion Models for CT Image Synthesis from CBCT: A Systematic Review
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Quantitative Consistency of Amide Proton Transfer-Weighted MRI for Brain Tumor Differentiation: Systematic Review of Clinical Evidence

1
Non-Human-Primate Imaging Center, Emory National Primate Research Center, Emory University, Atlanta, GA 30329, USA
2
Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA
3
Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30307, USA
4
Emory College of Arts and Sciences, Emory University, Atlanta, GA 30322, USA
5
Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
*
Author to whom correspondence should be addressed.
Tomography 2026, 12(5), 65; https://doi.org/10.3390/tomography12050065
Submission received: 28 February 2026 / Revised: 23 April 2026 / Accepted: 28 April 2026 / Published: 6 May 2026
(This article belongs to the Special Issue Celebrate the 10th Anniversary of Tomography)

Simple Summary

Significantly large heterogeneity in diagnostic accuracy measured by area under the curve (AUC) from receiver operating characteristic analysis and quantitative consistency measured by mean difference in amide proton transfer-weighted (APTw) MRI was observed and partially attributable to scan parameters, highlighting the need for full protocol reporting and standardization. Heterogeneity in mean difference was moderated by the total parameter set. Meta-regression suggests that the current set of imaging parameters could improve from further optimization. Moreover, outlier analysis suggests that parameterization of APTw MRI has yet to reach consensus.

Abstract

Background/Objectives: Accurate grading of brain gliomas is important, and amide proton transfer-weighted (APTw) MRI shows promise for non-invasive tumor differentiation. This study aimed to perform a comprehensive review and meta-analyses to demonstrate heterogeneity in both the diagnostic accuracy and quantitative consistency of APTw MRI in distinguishing high-grade gliomas (HGGs) from low-grade gliomas (LGGs), highlight issues with reporting standards and identify sources of heterogeneity through meta-regression. Methods: A systematic literature search was conducted between 1 January 2013 and 18 January 2026, following PRISMA guidelines. Peer-reviewed articles in English reporting diagnostic accuracy/contrast values of APTw MRI and study parameters were included. Principal component analysis (PCA) was used to extract the principal components (PCs) of the chemical exchange saturation transfer (CEST) contrast mechanism. Random-effects meta-analyses and univariate meta-regression models using individual CEST parameters and three PCs were performed. Forest plots with pooled estimates were generated. Leave-one-out meta-analysis (LOOMA) and complete case analysis were performed to examine the effects of outliers and missing data, respectively. Results: A total of 31 studies were included. Meta-analyses of the AUC and mean difference demonstrated significant heterogeneity across the studies (I2 = 73.9% & 78.2%, p < 0.001). The mean difference was moderated by one SD within the mean of the readout PC (p = 0.034) and the total PC (p = 0.02). The heterogeneity for the AUC and group mean difference was not substantially reduced by moderating nor LOOMA. The results of the meta-regression using all the data were similar to those using only data with no missing parameters. Conclusions: While APTw MRI shows promise for non-invasively distinguishing glioma grades, substantial heterogeneity in the study parameters limits generalizability. To improve consistency and comparability across studies, full reports of imaging parameters and standardization of APTw protocols are essential.

1. Introduction

Magnetic Resonance (MR) imaging plays an increasingly vital role in the diagnosis, characterization, and monitoring of brain tumors [1,2,3], with over 80,000 new cases being discovered every year [4]. A key driver for the continued expansion of MR imaging applications is its distinct tissue contrast that differentiates tumors from surrounding tissue [5]. The World Health Organization has established a glioma grading system based on histopathological and molecular features [6], categorizing tumors from low-grade (I/II) to high-grade (III/IV) [7]. Accurate tumor grading plays a critical role in prognosis estimation and treatment planning, directly impacting patient outcomes and quality of life.
Routine clinical brain tumor protocols often include structural, contrast-enhanced, diffusion [8] and perfusion scans [1,9], and even magnetic resonance spectroscopy [1,10,11]. However, studies have demonstrated the need for expanding the tools available for tumor imaging [12,13]. Over the last 20 years, chemical exchange saturation transfer (CEST) MRI has emerged as a sensitive approach to map mobile proteins/peptides and microenvironmental pH [14,15,16]. Amide proton transfer-weighted (APTw) MRI has been the most studied, which targets amide protons that are ubiquitous in the primary structure of mobile endogenous peptides and proteins. Studies have shown that APTw MRI is potentially more effective in grading these tumors than conventional imaging [17], as well as diffusion and perfusion MRI [18,19]. It has also shown promise in predicting tissue response to treatment, differentiating between tumor progression and treatment response [20,21], and identifying IDH mutation status [22,23,24,25], 1p/19q codeletion [26], and MGMT [24,27]. However, while the diagnostic potential of APTw imaging has been extensively studied, routine analysis often does not account for differences that govern the source of APTw contrast. Compared to other modalities, altering imaging parameters could substantially impact CEST contrast to the point where additional sources of CEST effects could potentially dilute the observed APTw contrast. Nevertheless, the potential impact of such scan parameters could be hard to assess if they are not fully reported, resulting in a difference in the cutoff values used for diagnostics, impairing quantification consistency across studies.
The diagnostic potential of CEST MRI arises from the interplay of several intrinsic and extrinsic parameters. To generate CEST contrast, a radiofrequency pulse is applied at a frequency resonant with a targeted labile proton group, and saturation is then transferred to the bulk tissue water pool during the Radio Frequency (RF) saturation, conferring the CEST contrast. As a result, the dilute labile proton signal and exchange properties can be amplified and inferred from the abundant water signal. For APTw imaging, beyond the chemical shift of the amide protons (approximately 3.5 ppm), two key intrinsic properties govern APT contrast: (1) the concentration of exchangeable amide protons, potentially reflective of increased protein synthesis during cell proliferation, and (2) the exchange rate of these protons with water, which is pH-dependent and may be modulated by metabolic changes, such as the Warburg effect. However, the complex interactions among these parameters and how they are influenced by the specifics of the MR pulse sequence are still under continuous study. This complexity has led to variation in APTw imaging protocols and processing across studies, particularly regarding the parameters of the CEST sequence. A summary of these parameters are described in Table 1.
CEST parameters can be broadly grouped into the following two factors. The first one is saturation: (a) average CEST RF B1 amplitude (B1 average, B1,avg) represents the average RF power applied during saturation. It modulates exchange rate sensitivity [15,28] and is distinct from peak B1, being related by duty cycle and pulse shape [29]. (b) CEST RF duty cycle (DC) defines the proportion of time during which saturation is applied relative to the total saturation duration (Tsat). Reduced duty cycles can suppress sensitivity to slow chemical exchanges compared to high duty cycles (e.g., continuous wave saturation) [30,31,32]. (c) CEST RF saturation time (Tsat) determines the degree to which the system approaches steady state under saturation. Fast-exchanging protons may exhibit maximal sensitivity in shorter durations, while slower exchanges exhibit maximal sensitivity in longer duration [28,33]. The second factor is the image readout: (a) Repetition Time (TR) is the time between successive saturation-readout cycles. TR influences relaxation recovery and, consequently, the reproducibility of the steady-state signal [34]. (b) The image readout type encompasses sequence characteristics, such as dimensionality (2D vs. 3D), echo type (gradient-echo vs. spin-echo), and vendor-specific implementations that can impact image timing and sensitivity. Exchange Rate Tuning parameters that affect the CEST saturation, together with CEST RF saturation frequency, determine which labile protons are imaged using CEST MRI, whether they are amide protons or other overlapping moieties. Read-out parameters primarily determine signal sensitivity, as they are independent of the applied saturation. Among these two groups of parameters, parameters related to timing affect the approximation of the exchange system as existing in a steady state, which simplifies many properties in CEST, in a similar way to how assumptions of equilibrium simplify reaction kinetics in the chemistry field. Together, these groupings may represent how these parameters could be considered with respect to the CEST mechanism.
Given the variability in both intrinsic and extrinsic factors affecting APT signal generation, there has been a persistent effort in standardizing and further optimizing scan parameters for APTw MRI, including a recent white paper in 2022 [35]. Nevertheless, there continue to be substantial differences in reported APTw MRI protocols across centers, raising questions about the reproducibility and generalizability of APT-derived metrics for brain tumor grading. Some of the reported studies did not fully report the scan parameters needed, as described above, to properly evaluate their imaging protocols for APTw MRI. While there have been meta-analyses that have studied the diagnostic accuracy of APT imaging by aggregating Area Under the Curve (AUC) values from Receiver Operating Characteristic (ROC) analyses, APTw MRI is semi-quantitative, and the reliability of the quantitative differences between glioma types must also be explored. Furthermore, while other differentiation diagnostics may hold additional clinical relevance, such as the differentiation of tumor recurrence from radiation necrosis, the volume of data regarding the differentiation between HGG and LGG is still the largest available for an in-depth analysis of imaging parameter relevance.
In this meta-analysis, we systematically identified and analyzed 31 studies [10,11,18,19,22,23,24,25,26,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57] that reported the use of APTw imaging for glioma grading and evaluated heterogeneity in both the diagnostic accuracy of APT imaging and the mean difference in contrast values between high-grade and low-grade gliomas. We observed the impact of incomplete parameter reporting and attempted to use principal component analysis to interpret decision-making behavior for parameter settings across various parameters with respect to their role in APTw imaging. Additionally, we explored whether the observed heterogeneity could be explained by variations in CEST imaging parameters using meta-regression. In addition, we quantify the results of our investigation by exploring two additional questions: 1. Using the first principal component of each set of parameters as a surrogate for similarity across parameters, does the average choice of parameters (or closest to the mean of the principal component) represent more optimized diagnostic accuracy or larger mean difference versus outliers (or S.D. outside of the mean)? 2. Using metrics such as leave-one-out meta-analysis (LOOMA), are there outliers for our meta-analysis of diagnostic accuracy (AUC) and quantitative consistency (M.D.), even with recent efforts to push for standardization of parameters and quantification?

2. Materials and Methods

2.1. The Search Strategy

This systematic review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [58]. A comprehensive computerized search of the PubMed, Medline, and Embase databases was performed to identify relevant studies published between 1 January 2013 and 18 January 2026 (described in the Supplementary Materials). The search aimed to assess the diagnostic performance and consistency of APTw MRI in glioma grading. The search terms were structured to capture the following three domains: (1) APT imaging, (2) brain tumor patients, and (3) glioma grading. These concepts were combined with Boolean operators and synonyms, as detailed in the Supplementary Materials. This study was conducted in strict accordance with a pre-defined internal protocol, which was registered retrospectively in the INPLASY register as INPLASY202640073 (10.37766/inplasy2026.4.0073). To ensure transparency and reproducibility, the research follows the PRISMA 2020 (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. All the methods, inclusion criteria, and analysis plans were established prior to the data extraction phase to minimize bias.

2.2. Inclusion Criteria

In order to build on previous analyses of diagnostic accuracy, eligible studies met the following criteria: published in English in a peer-reviewed journal; included patients with histopathologically confirmed gliomas, where biopsy served as the reference standard for tumor grading; employed pre-treatment APT imaging as the index test for glioma grading; and reported or provided sufficient data to derive ROC metrics, like sensitivity and specificity, but specifically AUC. They were subsequently analyzed to examine sufficient reporting standards to evaluate the quantitative consistency of the reported metrics. The exclusion criteria included the following: animal or laboratory studies, reviews, meta-analyses, case reports, conference abstracts or presentations, and studies lacking either histopathological confirmation or usable APT grading data.

2.3. Data Extraction

The data were extracted and organized using Microsoft Excel. The extracted variables included the following: study identifiers (author, year, sample size); group-specific APTw mean differences, standard deviations, and sample sizes; reported AUC values, including detailed CEST sequence parameters (magnetic field strength (B0), RF saturation amplitude (B1) and duration (Tsat), repetition time (TR)); image readout (e.g., spin-echo vs. gradient-echo, 2D vs. 3D); cutoff thresholds for classification; and three principal component (PC) scores derived from saturation preparation, magnetization recovery, and steady-state domains (see below). Quality assessment of the selected studies was performed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2; Supplementary Figure S1) [59].

2.4. Principal Component Analysis of Grouped Parameters

To investigate how technical parameters may influence APT contrast and diagnostic performance, CEST-related variables were grouped based on their role in the APT contrast mechanism: exchange rate tuning, read-out, and steady-state behavior. Each group of parameters were normalized by their mean and standard deviation and then underwent principal component analysis (PCA) to reduce dimensionality and extract eigenvectors representing the largest coherent variance across parameters in that group, with each additional sequential orthogonal eigenvector ordered down to the smallest variance. The first principal component from each group (i.e., the component with the highest eigenvalue) was retained for subsequent meta-regression. Specifically, we have the exchange PC, the readout PC, and the steady-state PC, whose groupings are derived conceptually based on their effect on CEST imaging, as denoted in Table 1. Each principal component was treated as a covariate in subsequent univariate meta-regression analyses to assess its moderating effect on diagnostic accuracy and APT contrast.

2.5. Statistical Analysis

We analyzed two outcomes of interest: AUC and mean difference between two groups using random-effects meta-analyses. For the AUC, the variance estimate of AUC was computed by the derivation set forward by Hanley et al. [60]. Let θ denote AUC, we have V a r θ = θ 1     θ   +   n 1     1 Q 1     θ 2   +   n 2     1 Q 2     θ 2 n 1 n 2 , where Q 1 = θ 2     θ ,   Q 2 = 2 θ 2 1   +   θ , and n 1 ,   n 2 are sample sizes for groups 1 and 2, respectively. Since the AUC value ranged from 0 to 1 and most of the reported AUC values were not on the boundaries, a logit transformation was applied to the raw estimates, while the delta method was used to compute the standard error (SE) of logit(AUC). The random-effects meta-analyses were performed on the transformed scale, and the results were transformed back to the original range between 0 and 1. The 95% confidence intervals of the AUC values for each study may be asymmetric due to the non-linear transformation. For the mean differences, the variance estimate of the mean difference was computed by pooled variance assuming unequal variance between the two groups. Let μ 1 ,   μ 2 , and δ be the sample mean intensity for group 1, the sample mean intensity for group 2, and the mean difference, respectively. We have V a r δ = v 1 n 1 + v 2 n 2 , where v 1 and v 2 are the sample variances for groups 1 and 2, respectively. No transformation was applied to the mean difference estimates for meta-analysis.
For both meta-analyses, forest plots with pooled estimates, 95% confidence intervals (CIs), and relative weights were presented. The I 2 and τ 2 statistics and p-values from the Cochran’s Q-test for residual heterogeneity were reported to quantify the heterogeneity of the selected studies [61,62]. Funnel plots and p-values from Egger’s tests were presented to examine the publication bias [63]. Meta-regression on selected CEST parameters and PCs was performed to identify the potential source of heterogeneity. To examine the study parameter specific outlier effect (parameter consensus), a binary variable indicating whether the PC value fell within its mean by 1 SD was created, denoted as PC within 1 SD. Studies with unknown CEST parameters were removed for meta-regression. To address the heterogeneity introduced by changes in glioma classification over time, an indicator of publication time was included. The indicator had three categories: 2007–2016, 2017–2021, and 2022-present. The meta regression analyses were fitted with one CEST parameter each time for feature screening. The p-values from the omnibus test for moderators and I 2 and τ 2 statistics were reported to quantify the statistical significance of certain CEST parameters on the variability of the AUC values and mean differences across the studies.
Since data imputation is usually performed on the subject level within each study conditional on observed covariates of other subjects, it is not applicable to our case, as missing parameters are study-specific. To address the issue with varying levels of missing study parameters, we performed a sensitivity check on meta-analysis and meta-regression using a more restrictive complete-case only analysis in addition to the liberal case, which maximizes the sample size by including studies that may have missing parameters, provided those parameters do not preclude the analysis itself. For the restrictive case, we excluded any studies with incomplete parameters of interest. In this case, the number of articles was consistent with all the moderator analyses. To make the results convenient to read, we show the results under two conditions in parallel and specifically marked the number of missing studies. Finally, since missing covariates did not affect the forest plot nor the funnel plot, we did not include those plots from the complete case analysis.
To examine the outlier issue, we adopted the conventional approach: leave-one-out meta-analysis (LOOMA). We reran the meta-analysis by excluding each study. The updated I2 and tau2 statistics and p-values from the Cochran’s Q-test for residual heterogeneity were reported. In addition, we produced a Baujat plot to identify studies that contributed most to heterogeneity with a high influence on the overall pooled measure. Studies with high-impact outliers appear on the top-right corner of the plot.
All the statistical analyses were performed in R Version 4.3.1 (Vienna, Austria) [64] with “metafor” package [65]. p-values smaller than 0.05 were considered statistically significant.

3. Results

Of the 635 studies initially reviewed, a total of 31 studies met the inclusion criteria and were incorporated into the meta-analysis (Figure 1). The study-level details—including AUC values, mean differences, comparison groups, sample sizes, and reported CEST parameters—are summarized in Table 2 and Table 3.
The principal components derived from grouping the CEST parameters are presented in Supplementary Tables S1–S4, along with a description of the corresponding eigenvectors. The variance across the exchange PC comprised 40%, which was only slightly more than in its orthogonal directions (32% and 29%), meaning there was not a strong consensus in the differences of these parameters across all the studies. Similarly, for a 1 S.D, movement along the exchange PC, 41% is along Tsat and 38% is increasing B1,sat, while 21% is decreasing DC. For the readout PC, nearly 66% of the variance was along the first two orthogonal directions (34% and 31%) out of 7 eigenvectors. Along the first PC for a 1 S.D, movement, 37% is along TR, and 36% is increasing Trec, underlying the importance of timing parameters. For the steady state PC, 67% of the variance is along TR and Tsat moving equally in the same direction. Across the entire parameter set, over half of the variance is explained by the first two eigenvectors (28% and 25%). For the first total PC, for a 1 S.D. change, 20% is along B1, with 14% and 12% being along timing parameters: Tsat and TR in the same direction.

3.1. Covariate-Free Meta-Analysis

All 31 studies reported AUC values for distinguishing LGG from HGG using APTw MRI, while only 24 studies reported the mean difference and SE in contrast values between the LGG and HGG groups.

3.1.1. AUC

The meta-analysis yielded a pooled AUC of 0.81 (95% CI: [0.78, 0.84]; Figure 2a). However, the AUC values ranged from 0.54 to 0.99. Significantly high heterogeneity was detected (I2 = 73.9%, τ2 = 0.2, p < 0.001). The funnel plot did indicate some potential publication bias, with 7 out of 31 studies (22.6%) falling outside the expected confidence limits (Figure 3a), and the Egger’s test confirmed this asymmetry (p < 0.001). The restrictive complete-case analysis showed similar heterogeneity: Among 19 studies, the I2 and τ2 values and p-value from residual heterogeneity were 83.0%, 0.33, and <0.001, respectively. Analysis of logit(AUC) is additionally presented in the Supplementary Materials (Figure S2).

3.1.2. Mean Difference

The pooled mean difference in contrast between the groups from the meta-analysis was 0.95 (95% CI: [0.80, 1.10]; Figure 2b). However, the reported values ranged from 0.23 to 1.84. Significantly high heterogeneity was detected with statistical significance (I2 = 78.2%, τ2 = 0.08, p < 0.001). The funnel plot for the mean difference in contrast between the groups also showed slight asymmetry, with 7 out of 24 studies (29.2%) outside the funnel bounds (Figure 3b), and Egger’s test returned a p-value of 0.06. However, a lack of asymmetry may not suggest a lack of publication bias. The restrictive complete case analysis showed similar heterogeneity: Among 18 studies, the I2 and τ2 values and p-value from residual heterogeneity were 75.5%, 0.084, and < 0.001, respectively.

3.2. Univariate Meta-Regression

To analyze potential moderators for heterogeneity, univariate meta-regression was performed on both AUC and the Mean Difference in Contrast between the groups. Moderators include each parameter, PCs from the parameter set, 1 SD outside each PC for consensus evaluation, and a time indicator to reflect the protocol change over time.

3.2.1. AUC

For the maximum sample scenario, none of the study parameters, PCs or their binary status within 1 SD, nor the time indicator showed statistical significance in moderating tests. The means of LGG and HGG and the group mean differences and cutoff values, despite significant moderating effects, were not included for meta-regression because they were not study parameters. With respect to parameter consensus, there was no demonstrable statistical significance between within and outside 1 SD of the mean for any of the first principal components of the parameter groups used for PCA, including the total set of parameters. The meta-regression results for the complete case analysis were similar with the only exception for saturation time. It reduced the I2 from 83.0% to 79.2% and accounted for 4.8% of the variability (p = 0.04 for the moderating effect). Detailed information can be found in Table 4.

3.2.2. Mean Difference

The total PC showed a significant moderating effect that reduced the total heterogeneity from 75.5% to 67.1% and accounted for 23.5% of the heterogeneity (p = 0.02). Despite the lack of statistical significance of read-out PC and steady-state PC, the consensus measure of read-out PC reduced the total heterogeneity from 75.5% to 68.9% and accounted for 23.1% of the variability (p = 0.034). In addition, the consensus measure of steady-state PC and total PC also reduced the total heterogeneity from 75.5% to 71.4% and 71.1% and accounted for 12.9% and 0.6% of the variability, respectively. The p-values for the omnibus moderator tests were both below 0.1. The meta-regression results by complete case analysis were also similar, except that the scanning dimensionality (3D vs. 2D) significantly reduced the heterogeneity from 75.5% to 62.4% and accounted for 39.0% of the variability (p = 0.031).
In this case, the average parameters currently utilized for read-out among the studies may not be optimized to provide maximal mean difference in APTw contrast between glioma groups. Detailed information can be found in Table 5.

3.3. Outlier Evaluation Using Baujat Plots and LOOMA

To examine the stability of the meta-analysis across the studies, outlier analysis was performed using leave-one-out meta-analysis (LOOMA; Table 6 and Table 7) and Baujat plots (Figure 4).

3.3.1. AUC

LOOMA revealed that omission of Zhang et al. [51] 2018 resulted in a 30.9% reduction in I2 and a 60% reduction in τ2 (Table 5). Looking at the Baujat plots for AUC (Figure 4a), the main studies with the largest Pearson residuals with large influence on the pooled AUC values were Hou et al. [23] 2024, Zou et al. [53] 2017, and Zhang et al. [51] 2018. Although the field had developed as of 2024, some outlying studies were still forthcoming. The omission of each study did not substantially resolve the heterogeneity issue, as an I2 of 52% was still considered moderate.

3.3.2. Mean Difference in Contrast Comparing LGG to HGG

LOOMA revealed that omission of Ying et al. [54] 2025 and Yegnaraman et al. resulted in a 5.55/4.34% reduction in I2 and a 25/25% reduction in τ2, respectively (Table 6). Yegnaraman et al. [55] 2025, Park et al. [44] 2015b, Ying et al. [54] 2025, and Sakata et al. [46] 2018 were the main studies that had large Pearson residuals with large influence on the pooled mean difference in contrast (Figure 4b). The I2 values after LOOMA on the mean difference in contrast comparing LGG to HGG were still larger than 70%, indicating high heterogeneity. In addition, the most significant outliers in LOOMA that were also identified by the Baujat plots were both published in 2025, suggesting that the field of study has not come to a stable consensus yet for the mean difference in APTw contrast between glioma groups.

4. Discussion

Our study conducted a systematic literature review and meta-analyses of 31 studies evaluating the diagnostic utility and quantitative consistency of APT imaging for distinguishing HGG from LGG to highlight the large heterogeneity among existing studies and the need for standardized protocols and reporting of parameters and results. While previous meta-analyses [66,67,68] have been performed to study diagnostic performance through AUC values, due to the importance of communicability between groups, we have extended the analysis to the consistency of the quantitative mean difference in measured contrast between groups. As CEST sensitivity is essentially a semi-quantitative value, the impact of study parameters on the heterogeneity of the gross difference measured in contrast between groups is crucial to its communicative value between study groups. We performed both meta-analyses and univariate meta-regression to explore the influence of individual imaging parameters, principal component transformations of the total parameter set, three sub-groups of parameters, and a time indicator on the observed outcomes.
In concurrence with previous studies, we found, along with the mean difference in contrast (I2 > 75%), the AUC exhibited significant heterogeneity (I2 > 70%). The I2 values after LOOMA for AUC and mean difference were still moderate to large, indicating that the omission of studies did not substantially resolve the heterogeneity issue and motivated us to find potential moderators to account for the large heterogeneity. While Suh et al. [67] identified B1 as a significant moderator for AUC heterogeneity, with the addition of recent studies, neither B1 nor any other single parameter has a significant effect in moderating AUC heterogeneity when using a liberal approach using all study data available. We added a sensitivity check running the regression with a restricted set of studies reduced to only studies that reported all parameters needed to validate their APTw protocol. In contrast, when using a more restrictive approach, saturation time is a significant moderator for heterogeneity. To understand why the smaller set that properly reported parameters may exhibit more specific significance, we attempted to analyze the behavior in the parameter setting using PCA. We found that while parameters related to read-out or steady state did exhibit some coherence, especially with respect to timing parameters, parameters related to exchange rate were modulated with significantly less coherence. This lack of parameter coherence with respect to mechanism may have muddied any correlation with individual parameters in attempting to establish linkages through univariate regression.
Like the liberal regression for AUC, there were no regressors among the individual parameters for heterogeneity in the mean difference in contrast between the groups; however, analyzing the grouped parameters with principal component analysis revealed moderators in the primary principal components across all the parameters and near significance for parameters moderating the exchange rate tuning of APTw contrast. On the other hand, when running a restricted analysis, the dimensionality of the read-out became a significant moderator of heterogeneity in the mean difference between the groups along with the total PC.
These findings reinforce the need to standardize imaging protocols and, at the very least, the need to consistently report all imaging parameters. Our analysis comparing within a standardization of the mean of the first principal component of sets of parameters has demonstrated that there is yet to be a set of parameters that proves statistically optimal over outliers for diagnostic accuracy or quantitative consistency. In fact, analysis of the readout PC suggests that the current average parameters for readout may be suboptimal in maximizing the mean difference in contrast. Furthermore, the yet persisting report of outlying studies suggests that the field could benefit from further consensus.
One drawback in our study is the change in grading standards for high- and low-grade gliomas with the release of new WHO guidelines in 2007, 2016, and 2021. These guideline changes mark technological upgrades in classification from pure histology to the use of molecular markers to full molecular integration, which may impact grading standards. Unfortunately, using only the data reported in these papers, exact harmonization is untenable. Instead, we ran a sensitivity analysis using a time indicator to test the significance of these landmark changes and were unable to determine any statistical significance for time periods across these guideline changes.
Another key weakness in our analysis is that the volume of studies gathered for analysis was undermined by insufficient consistency in reporting standards for crucial parameters that are vital for understanding CEST behavior. Out of the 31 studies included, only 19 studies reported the minimum parameters required to qualify their APTw imaging protocol. For CEST, a change in imaging parameters can substantially change the imaging modality and the imaged moiety. Efforts to improve inter-study comparability should include broader adoption of standardized guidelines, such as those proposed in the clinical APT consensus paper [35], as well as efforts to harmonize study parameters once optimization is achieved. In addition to standardized protocols, the implementation of quantitative standardization techniques [54,69,70] may help minimize variability introduced by sequence parameters by harmonizing the influence of these parameters on output maps or enabling the calculation of parametric maps with more direct physiological meaning [71,72]. Moreover, routine reporting of the saturation module and readout parameters, especially those influencing exchange rate sensitivity, is necessary. Together, these initiatives can reduce the interpretive ambiguity caused by parameter heterogeneity and promote the reliable use of APT imaging as a biomarker in glioma diagnostics.

5. Conclusions

While APTw MRI shows promise for non-invasively distinguishing glioma grades, substantial heterogeneity in study parameters limits its generalizability. Significant heterogeneity was demonstrated in both diagnostic accuracy and quantitative consistency. While individual parameters alone were insufficient to moderate heterogeneity, PCA has revealed that the total parameter set does, in fact, moderate the heterogeneity of the quantitative difference between glioma groups. Meta-regression suggests the current set of imaging parameters could still benefit from further optimization, and the existence of recent outliers suggests that standardization of APTw MRI has yet to reach consensus. To improve consistency and comparability across studies, full reports of imaging parameters and standardization of APTw protocols are essential.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/tomography12050065/s1. Supplementary Materials S1—Search List, Principal Component Analysis; Supplementary Materials S2—PRISMA Checklist [73]; Table S1: Exchange Principal Component: Exchange Rate Tuning; Table S2: Read-Out Principal Component: Magnetization Recovery; Table S3: Steady-state PC; Table S4: Total Principal Component: Total Parameters; Figure S1: QUADAS-2: Quality Assessment Results; Figure S2: Forest plot of logit(AUC) comparing LGG to HGG among 31 studies.

Author Contributions

Conceptualization, J.J.C., T.M. and P.Z.S.; methodology, T.M. and J.J.C.; soft-ware, T.M. and J.J.C.; validation, J.J.C., T.M., P.P. and T.Z.; formal analysis, T.M. and J.J.C.; investigation, T.M., J.J.C., T.Z. and P.P.; resources, P.Z.S. and A.E.G.-Y.; data curation, J.J.C. and T.Z.; writing—original draft preparation, J.J.C. and T.M.; writing—review and editing, J.J.C., T.M. and P.Z.S.; visualization, T.M., J.J.C. and T.Z.; supervision, P.Z.S. and A.E.G.-Y.; project administration, P.Z.S. and A.E.G.-Y.; funding acquisition, P.Z.S. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported in part by 2R01NS083654, I3 Medical Technology Research Award from Emory School of Medicine, Georgia Clinical and Translational Award, National Center for Advancing Translational Sciences (NCATS, UL1–TR002378), Georgia Tech/Emory Biolocity program support, and P51OD011132 to Emory National Primate Research Center.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data generated by the authors or analyzed during this study were extracted from the studies analyzed and are available with their doi in the following references: References [10,11,18,19,22,23,24,25,26,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57].

Conflicts of Interest

Sun has contributed as an inventor to a patent for the quasi-steady-state (QUASS) CEST MRI algorithm for standardization of CEST data. Emory University owns and manages the patent.

Abbreviations

The following abbreviations are used in this manuscript:
APTwAmide Proton Transfer-weighted
RFRadio Frequency
SDStandard Deviation
CIConfidence Interval
NpNumber of Pulses
B1,avgAverage B1
HGGHigh-Grade Glioma
LGGLow-Grade Glioma
PCAPrincipal Component Analysis
CESTChemical Exchange Saturation Transfer
AUCArea Under the Curve
ROCReceiver Operating Characteristic
SESpin-Echo
TSETurbo Spin-Echo
FSEFast Spin-Echo
GREGradient Echo
EPIEcho-Planar Imaging
GRASEGradient and Spin Echo
SPACESampling Perfection with Application optimized Contrasts using different flip angle Evolution

References

  1. Law, M.; Yang, S.; Wang, H.; Babb, J.S.; Johnson, G.; Cha, S.; Knopp, E.A.; Zagzag, D. Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am. J. Neuroradiol. 2003, 24, 1989–1998. [Google Scholar] [PubMed]
  2. Weissleder, R.; Pittet, M.J. Imaging in the era of molecular oncology. Nature 2008, 452, 580–589. [Google Scholar] [CrossRef] [PubMed]
  3. Watanabe, M.; Tanaka, R.; Takeda, N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 1992, 34, 463–469. [Google Scholar] [CrossRef]
  4. Miller, K.D.; Ostrom, Q.T.; Kruchko, C.; Patil, N.; Tihan, T.; Cioffi, G.; Fuchs, H.E.; Waite, K.A.; Jemal, A.; Siegel, R.L.; et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J. Clin. 2021, 71, 381–406. [Google Scholar] [CrossRef]
  5. Dean, B.L.; Drayer, B.P.; Bird, C.R.; Flom, R.A.; Hodak, J.A.; Coons, S.W.; Carey, R.G. Gliomas: Classification with MR imaging. Radiology 1990, 174, 411–415. [Google Scholar] [CrossRef]
  6. Louis, D.N.; Perry, A.; Burger, P.; Ellison, D.W.; Reifenberger, G.; von Deimling, A.; Aldape, K.; Brat, D.; Collins, V.P.; Eberhart, C.; et al. International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014, 24, 429–435. [Google Scholar] [CrossRef]
  7. Louis, D.N.; Perry, A.; Wesseling, P.; Brat, D.J.; Cree, I.A.; Figarella-Branger, D.; Hawkins, C.; Ng, H.K.; Pfister, S.M.; Reifenberger, G.; et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro-Oncology 2021, 23, 1231–1251. [Google Scholar] [CrossRef]
  8. Guo, Y.; Ma, Z.; Pei, D.; Duan, W.; Guo, Y.; Liu, Z.; Guan, F.; Wang, Z.; Xing, A.; Guo, Z.; et al. Improving Noninvasive Classification of Molecular Subtypes of Adult Gliomas With Diffusion-Weighted MR Imaging: An Externally Validated Machine Learning Algorithm. J. Magn. Reson. Imaging 2023, 58, 1234–1242. [Google Scholar] [CrossRef]
  9. Knopp, E.A.; Cha, S.; Johnson, G.; Mazumdar, A.; Golfinos, J.G.; Zagzag, D.; Miller, D.C.; Kelly, P.J.; Kricheff, I.I. Glial neoplasms: Dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999, 211, 791–798. [Google Scholar] [CrossRef]
  10. Park, J.E.; Kim, H.S.; Park, K.J.; Kim, S.J.; Kim, J.H.; Smith, S.A. Pre- and Posttreatment Glioma: Comparison of Amide Proton Transfer Imaging with MR Spectroscopy for Biomarkers of Tumor Proliferation. Radiology 2016, 278, 514–523. [Google Scholar] [CrossRef] [PubMed]
  11. Sakata, A.; Fushimi, Y.; Okada, T.; Arakawa, Y.; Kunieda, T.; Minamiguchi, S.; Kido, A.; Sakashita, N.; Miyamoto, S.; Togashi, K. Diagnostic performance between contrast enhancement, proton MR spectroscopy, and amide proton transfer imaging in patients with brain tumors. J. Magn. Reson. Imaging 2017, 46, 732–739. [Google Scholar] [CrossRef]
  12. Eidel, O.; Burth, S.; Neumann, J.O.; Kieslich, P.J.; Sahm, F.; Jungk, C.; Kickingereder, P.; Bickelhaupt, S.; Mundiyanapurath, S.; Baumer, P.; et al. Tumor Infiltration in Enhancing and Non-Enhancing Parts of Glioblastoma: A Correlation with Histopathology. PLoS ONE 2017, 12, e0169292. [Google Scholar] [CrossRef]
  13. Kondziolka, D.; Lunsford, L.D.; Martinez, A.J. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J. Neurosurg. 1993, 79, 533–536. [Google Scholar] [CrossRef] [PubMed]
  14. Consolino, L.; Anemone, A.; Capozza, M.; Carella, A.; Irrera, P.; Corrado, A.; Dhakan, C.; Bracesco, M.; Longo, D.L. Non-invasive Investigation of Tumor Metabolism and Acidosis by MRI-CEST Imaging. Front. Oncol. 2020, 10, 161. [Google Scholar] [CrossRef]
  15. Jin, T.; Wang, P.; Hitchens, T.K.; Kim, S.G. Enhancing sensitivity of pH-weighted MRI with combination of amide and guanidyl CEST. Neuroimage 2017, 157, 341–350. [Google Scholar] [CrossRef] [PubMed]
  16. Jones, K.M.; Pollard, A.C.; Pagel, M.D. Clinical applications of chemical exchange saturation transfer (CEST) MRI. J. Magn. Reson. Imaging 2018, 47, 11–27. [Google Scholar] [CrossRef]
  17. Zhou, J.; Blakeley, J.O.; Hua, J.; Kim, M.; Laterra, J.; Pomper, M.G.; van Zijl, P.C. Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magn. Reson. Med. 2008, 60, 842–849. [Google Scholar] [CrossRef]
  18. Choi, Y.S.; Ahn, S.S.; Lee, S.K.; Chang, J.H.; Kang, S.G.; Kim, S.H.; Zhou, J. Amide proton transfer imaging to discriminate between low- and high-grade gliomas: Added value to apparent diffusion coefficient and relative cerebral blood volume. Eur. Radiol. 2017, 27, 3181–3189. [Google Scholar] [CrossRef]
  19. Togao, O.; Hiwatashi, A.; Yamashita, K.; Kikuchi, K.; Keupp, J.; Yoshimoto, K.; Kuga, D.; Yoneyama, M.; Suzuki, S.O.; Iwaki, T.; et al. Grading diffuse gliomas without intense contrast enhancement by amide proton transfer MR imaging: Comparisons with diffusion- and perfusion-weighted imaging. Eur. Radiol. 2017, 27, 578–588. [Google Scholar] [CrossRef] [PubMed]
  20. Park, K.J.; Kim, H.S.; Park, J.E.; Shim, W.H.; Kim, S.J.; Smith, S.A. Added value of amide proton transfer imaging to conventional and perfusion MR imaging for evaluating the treatment response of newly diagnosed glioblastoma. Eur. Radiol. 2016, 26, 4390–4403. [Google Scholar] [CrossRef]
  21. Essed, R.A.; Prysiazhniuk, Y.; Wamelink, I.J.; Azizova, A.; Keil, V.C. Performance of amide proton transfer imaging to differentiate true progression from therapy-related changes in gliomas and metastases. Eur. Radiol. 2025, 35, 580–591. [Google Scholar] [CrossRef] [PubMed]
  22. Guo, H.; Liu, J.; Hu, J.; Zhang, H.; Zhao, W.; Gao, M.; Zhang, Y.; Yang, G.; Cui, Y. Diagnostic performance of gliomas grading and IDH status decoding A comparison between 3D amide proton transfer APT and four diffusion-weighted MRI models. J. Magn. Reson. Imaging 2022, 56, 1834–1844. [Google Scholar] [CrossRef]
  23. Hou, H.; Yu, J.; Diao, Y.; Xu, M.; Li, Z.; Song, T.; Liu, Y.; Wang, L. Diagnostic performance of multiparametric nonenhanced magnetic resonance imaging (MRI) in grading glioma and correlating IDH mutation status. Clin. Radiol. 2025, 82, 106791. [Google Scholar] [CrossRef] [PubMed]
  24. Paech, D.; Windschuh, J.; Oberhollenzer, J.; Dreher, C.; Sahm, F.; Meissner, J.E.; Goerke, S.; Schuenke, P.; Zaiss, M.; Regnery, S.; et al. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. Neuro-Oncology 2018, 20, 1661–1671. [Google Scholar] [CrossRef]
  25. Xu, Z.; Ke, C.; Liu, J.; Xu, S.; Han, L.; Yang, Y.; Qian, L.; Liu, X.; Zheng, H.; Lv, X.; et al. Diagnostic performance between MR amide proton transfer (APT) and diffusion kurtosis imaging (DKI) in glioma grading and IDH mutation status prediction at 3 T. Eur. J. Radiol. 2021, 134, 109466. [Google Scholar] [CrossRef]
  26. Su, C.; Xu, S.; Lin, D.; He, H.; Chen, Z.; Damen, F.C.; Ke, C.; Lv, X.; Cai, K. Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients. Eur. Radiol. 2022, 32, 101–111. [Google Scholar] [CrossRef]
  27. Jiang, S.; Rui, Q.; Wang, Y.; Heo, H.Y.; Zou, T.; Yu, H.; Zhang, Y.; Wang, X.; Du, Y.; Wen, X.; et al. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics. Eur. Radiol. 2018, 28, 2115–2123. [Google Scholar] [CrossRef] [PubMed]
  28. Jin, T.; Kim, S.G. Advantages of chemical exchange-sensitive spin-lock (CESL) over chemical exchange saturation transfer (CEST) for hydroxyl- and amine-water proton exchange studies. NMR Biomed. 2014, 27, 1313–1324. [Google Scholar] [CrossRef]
  29. Lankford, C.L.; Louie, E.A.; Zu, Z.; Does, M.D.; Gochberg, D.F. A hybrid numeric-analytic solution for pulsed CEST. NMR Biomed. 2022, 35, e4610. [Google Scholar] [CrossRef]
  30. Chung, J.J.; Jin, T. Low duty cycle pulse trains for exchange rate insensitive chemical exchange saturation transfer MRI. Magn. Reson. Med. 2021, 86, 2542–2551. [Google Scholar] [CrossRef]
  31. Jin, T.; Chung, J.J. Average saturation efficiency filter (ASEF) for CEST imaging. Magn. Reson. Med. 2022, 88, 254–265. [Google Scholar] [CrossRef]
  32. Chung, J.J.; Jin, T. Average saturation efficiency filter ASEF-CEST MRI of stroke rodents. Magn. Reson. Med. 2023, 89, 565–576. [Google Scholar] [CrossRef]
  33. Jin, T.; Wang, P.; Zong, X.; Kim, S.G. Magnetic resonance imaging of the Amine-Proton EXchange (APEX) dependent contrast. Neuroimage 2012, 59, 1218–1227. [Google Scholar] [CrossRef]
  34. Jiang, W.; Zhou, I.Y.; Wen, L.; Zhou, X.; Sun, P.Z. A theoretical analysis of chemical exchange saturation transfer echo planar imaging (CEST-EPI) steady state solution and the CEST sensitivity efficiency-based optimization approach. Contrast Media Mol. Imaging 2016, 11, 415–423. [Google Scholar] [CrossRef]
  35. Zhou, J.; Zaiss, M.; Knutsson, L.; Sun, P.Z.; Ahn, S.S.; Aime, S.; Bachert, P.; Blakeley, J.O.; Cai, K.; Chappell, M.A.; et al. Review and consensus recommendations on clinical APT-weighted imaging approaches at 3T: Application to brain tumors. Magn. Reson. Med. 2022, 88, 546–574. [Google Scholar] [CrossRef]
  36. Bai, Y.; Lin, Y.; Zhang, W.; Kong, L.; Wang, L.; Zuo, P.; Vallines, I.; Schmitt, B.; Tian, J.; Song, X.; et al. Noninvasive amide proton transfer magnetic resonance imaging in evaluating the grading and cellularity of gliomas. Oncotarget 2017, 8, 5834–5842. [Google Scholar] [CrossRef] [PubMed]
  37. Chen, Y.; Li, X.; Song, Y.; Zhu, X.; Zhao, J.; Yan, X.; Wang, J.; Fan, M.; Chu, J. The diagnostic efficacy of amide proton transfer imaging in grading gliomas and predicting tumor proliferation. Neuroreport 2019, 30, 139–144. [Google Scholar] [CrossRef]
  38. Debnath, A.; Gupta, R.K.; Reddy, R.; Singh, A. Effect of offset-frequency step size and interpolation methods on chemical exchange saturation transfer MRI computation in human brain. NMR Biomed. 2021, 34, e4468. [Google Scholar] [CrossRef] [PubMed]
  39. Durmo, F.; Rydhog, A.; Testud, F.; Latt, J.; Schmitt, B.; Rydelius, A.; Englund, E.; Bengzon, J.; van Zijl, P.; Knutsson, L.; et al. Assessment of Amide proton transfer weighted (APTw) MRI for pre-surgical prediction of final diagnosis in gliomas. PLoS ONE 2020, 15, e0244003. [Google Scholar] [CrossRef] [PubMed]
  40. Filimonova, E.; Pashkov, A.; Borisov, N.; Kalinovsky, A.; Rzaev, J. Utilizing the amide proton transfer technique to characterize diffuse gliomas based on the WHO 2021 classification of CNS tumors. Neuroradiol. J. 2024, 37, 490–499. [Google Scholar] [CrossRef]
  41. Hou, H.; Chen, W.; Diao, Y.; Wang, Y.; Zhang, L.; Wang, L.; Xu, M.; Yu, J.; Song, T.; Liu, Y.; et al. 3D Amide Proton Transfer-Weighted Imaging for Grading Glioma and Correlating IDH Mutation Status: Added Value to 3D Pseudocontinuous Arterial Spin Labelling Perfusion. Mol. Imaging Biol. 2023, 25, 343–352. [Google Scholar] [CrossRef] [PubMed]
  42. Kang, X.W.; Xi, Y.B.; Liu, T.T.; Wang, N.; Zhu, Y.Q.; Wang, X.R.; Guo, F. Grading of Glioma: Combined diagnostic value of amide proton transfer weighted, arterial spin labeling and diffusion weighted magnetic resonance imaging. BMC Med. Imaging 2020, 20, 50. [Google Scholar] [CrossRef]
  43. Liu, R.; Wang, X.; Zhao, Z.; Wen, Q.; Liu, T.; Wu, D.; Wen, Z.; Zhang, Y. A comparative study of quantitative metrics in chemical exchange saturation transfer imaging for grading gliomas in adults. Magn. Reson. Imaging 2023, 96, 50–59. [Google Scholar] [CrossRef]
  44. Park, J.E.; Kim, H.S.; Park, K.J.; Choi, C.G.; Kim, S.J. Histogram Analysis of Amide Proton Transfer Imaging to Identify Contrast-enhancing Low-Grade Brain Tumor That Mimics High-Grade Tumor: Increased Accuracy of MR Perfusion. Radiology 2015, 277, 151–161. [Google Scholar] [CrossRef]
  45. Sakata, A.; Okada, T.; Yamamoto, A.; Kanagaki, M.; Fushimi, Y.; Okada, T.; Dodo, T.; Arakawa, Y.; Schmitt, B.; Miyamoto, S.; et al. Grading glial tumors with amide proton transfer MR imaging: Different analytical approaches. J. Neurooncol. 2015, 122, 339–348. [Google Scholar] [CrossRef]
  46. Sakata, A.; Okada, T.; Yamamoto, Y.; Fushimi, Y.; Dodo, T.; Arakawa, Y.; Mineharu, Y.; Schmitt, B.; Miyamoto, S.; Togashi, K. Addition of Amide Proton Transfer Imaging to FDG-PET/CT Improves Diagnostic Accuracy in Glioma Grading: A Preliminary Study Using the Continuous Net Reclassification Analysis. AJNR Am. J. Neuroradiol. 2018, 39, 265–272. [Google Scholar] [CrossRef] [PubMed]
  47. Su, C.; Jiang, J.; Liu, C.; Shi, J.; Li, S.; Chen, X.; Ao, Q. Comparison of amide proton transfer imaging and magnetization transfer imaging in revealing glioma grades and proliferative activities: A histogram analysis. Neuroradiology 2021, 63, 685–693. [Google Scholar] [CrossRef] [PubMed]
  48. Su, C.; Li, S.; Chen, X.; Liu, C.; Shaghaghi, M.; Jiang, J.; Zhang, S.; Qin, Y.; Cai, K. Predicting cancer malignancy and proliferation in glioma patients: Intra-subject inter-metabolite correlation analyses using MRI and MRSI contrast scans. Quant. Imaging Med. Surg. 2021, 11, 2721–2732. [Google Scholar] [CrossRef]
  49. Su, C.; Liu, C.; Zhao, L.; Jiang, J.; Zhang, J.; Li, S.; Zhu, W.; Wang, J. Amide Proton Transfer Imaging Allows Detection of Glioma Grades and Tumor Proliferation: Comparison with Ki-67 Expression and Proton MR Spectroscopy Imaging. AJNR Am. J. Neuroradiol. 2017, 38, 1702–1709. [Google Scholar] [CrossRef]
  50. Zhang, H.W.; Liu, X.L.; Zhang, H.B.; Li, Y.Q.; Wang, Y.L.; Feng, Y.N.; Deng, K.; Lei, Y.; Huang, B.; Lin, F. Differentiation of Meningiomas and Gliomas by Amide Proton Transfer Imaging: A Preliminary Study of Brain Tumour Infiltration. Front. Oncol. 2022, 12, 886968. [Google Scholar] [CrossRef]
  51. Zhang, J.; Zhu, W.; Tain, R.; Zhou, X.J.; Cai, K. Improved Differentiation of Low-Grade and High-Grade Gliomas and Detection of Tumor Proliferation Using APT Contrast Fitted from Z-Spectrum. Mol. Imaging Biol. 2018, 20, 623–631. [Google Scholar] [CrossRef]
  52. Zhou, J.; Zhu, H.; Lim, M.; Blair, L.; Quinones-Hinojosa, A.; Messina, S.A.; Eberhart, C.G.; Pomper, M.G.; Laterra, J.; Barker, P.B.; et al. Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. J. Magn. Reson. Imaging 2013, 38, 1119–1128. [Google Scholar] [CrossRef]
  53. Zou, T.; Yu, H.; Jiang, C.; Wang, X.; Jiang, S.; Rui, Q.; Mei, Y.; Zhou, J.; Wen, Z. Differentiating the histologic grades of gliomas preoperatively using amide proton transfer-weighted (APTW) and intravoxel incoherent motion MRI. NMR Biomed. 2018, 31, e3850. [Google Scholar] [CrossRef] [PubMed]
  54. Ying, Y.; Wang, D.; Zhao, Y.; Quan, K.; Li, X.; Xie, Y.; Mei, N.; Chen, J.; Ruan, Z.; Xu, R.; et al. The Application of Quasi-Steady-State Chemical Exchange Saturation Transfer Imaging in the Visualization of Glioma Infiltration and the Optimal Extent of Resection Establishment. J. Magn. Reson. Imaging 2025, 62, 480–493. [Google Scholar] [CrossRef]
  55. Yegnaraman, L.; Chidambaranathan, N.; Rajendran, A. Preoperative Grading of WHO Grade 3 Gliomas and Comprehensive Glioma Assessment Using APTw MRI: Enhancing Diagnostic Thresholds and Noninvasive Tumor Characterization. NMR Biomed. 2025, 38, e70158. [Google Scholar] [CrossRef]
  56. Takami, Y.; Norikane, T.; Kimura, N.; Mitamura, K.; Manabe, Y.; Murao, M.; Yamamoto, Y.; Miyake, K.; Miyoshi, M.; Nishiyama, Y. Multi-pool model-based amide proton transfer imaging in grading of gliomas and evaluating tumor proliferation: Comparison to apparent diffusion coefficient and magnetization transfer ratio asymmetry. Magn. Reson. Imaging 2025, 123, 110488. [Google Scholar] [CrossRef] [PubMed]
  57. Jiang, T.; Wu, M.; Hu, J.; Guo, H.; Ma, X.; Liu, Y.; Zhang, Y. Multicenter validation of amide proton transfer imaging for the classification of adult-type diffuse gliomas. Magn. Reson. Imaging 2026, 127, 110599. [Google Scholar] [CrossRef] [PubMed]
  58. Page, M.J.; Moher, D.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ 2021, 372, n160. [Google Scholar] [CrossRef]
  59. Whiting, P.F.; Rutjes, A.W.; Westwood, M.E.; Mallett, S.; Deeks, J.J.; Reitsma, J.B.; Leeflang, M.M.; Sterne, J.A.; Bossuyt, P.M.; QUADAS-2 Group. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 2011, 155, 529–536. [Google Scholar] [CrossRef]
  60. Hanley, J.A.; McNeil, B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143, 29–36. [Google Scholar] [CrossRef]
  61. Higgins, J.P.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21, 1539–1558. [Google Scholar] [CrossRef]
  62. Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557–560. [Google Scholar] [CrossRef]
  63. Egger, M.; Davey Smith, G.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315, 629–634. [Google Scholar] [CrossRef]
  64. R: A Language and Environment for Statistical Computing, Version 4.3.1; R Foundation for Statistical Computing: Vienna, Austria, 2021. Available online: https://www.R-project.org/ (accessed on 1 January 2013).
  65. Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. J. Stat. Softw. 2010, 36, 1–48. [Google Scholar] [CrossRef]
  66. Sotirios, B.; Demetriou, E.; Topriceanu, C.C.; Zakrzewska, Z. The role of APT imaging in gliomas grading: A systematic review and meta-analysis. Eur. J. Radiol. 2020, 133, 109353. [Google Scholar] [CrossRef] [PubMed]
  67. Suh, C.H.; Park, J.E.; Jung, S.C.; Choi, C.G.; Kim, S.J.; Kim, H.S. Amide proton transfer-weighted MRI in distinguishing high- and low-grade gliomas: A systematic review and meta-analysis. Neuroradiology 2019, 61, 525–534. [Google Scholar] [CrossRef]
  68. Zhao, J.; Huang, S.; Xie, H.; Li, W. An evidence-based approach to evaluate the accuracy of amide proton transfer-weighted MRI in characterization of gliomas. Medicine 2019, 98, e14768. [Google Scholar] [CrossRef]
  69. Kim, H.; Krishnamurthy, L.C.; Sun, P.Z. Demonstration of fast multi-slice quasi-steady-state chemical exchange saturation transfer (QUASS CEST) human brain imaging at 3T. Magn. Reson. Med. 2022, 87, 810–819. [Google Scholar] [CrossRef] [PubMed]
  70. Sun, P.Z. Quasi-steady state chemical exchange saturation transfer (QUASS CEST) analysis-correction of the finite relaxation delay and saturation time for robust CEST measurement. Magn. Reson. Med. 2021, 85, 3281–3289. [Google Scholar] [CrossRef] [PubMed]
  71. Chung, J.J.; Kim, H.; Ji, Y.; Lu, D.; Zhou, I.Y.; Sun, P.Z. Improving standardization and accuracy of in vivo omega plot exchange parameter determination using rotating-frame model-based fitting of quasi-steady-state Z-spectra. Magn. Reson. Med. 2025, 93, 151–165. [Google Scholar] [CrossRef]
  72. Ji, Y.; Lu, D.; Sun, P.Z.; Zhou, I.Y. In vivo pH mapping with omega plot-based quantitative chemical exchange saturation transfer MRI. Magn. Reson. Med. 2023, 89, 299–307. [Google Scholar] [CrossRef] [PubMed]
  73. McInnes, M.D.F.; Moher, D.; Thombs, B.D.; McGrath, T.A.; Bossuyt, P.M.; The PRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA 2018, 319, 388–396. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Prisma flowchart detailing the literature search and screening process.
Figure 1. Prisma flowchart detailing the literature search and screening process.
Tomography 12 00065 g001
Figure 2. Forest plots of AUC (a) and Difference of Mean Contrast (b) comparing LGG to HGG among 31 studies [10,11,18,19,22,23,24,25,26,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57]. Seven studies were excluded in (b) due to unknown mean or SE values. The I2 heterogeneity measure, τ2 (absolute measure of variance of the true effect sizes across studies), and p-value for Cochran’s Q test for residual heterogeneity were 73.9%, 0.2, and <0.001 for AUC, respectively and for the Mean Difference in Contrast they were 78.2%, 0.08, and <0.001, respectively.
Figure 2. Forest plots of AUC (a) and Difference of Mean Contrast (b) comparing LGG to HGG among 31 studies [10,11,18,19,22,23,24,25,26,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57]. Seven studies were excluded in (b) due to unknown mean or SE values. The I2 heterogeneity measure, τ2 (absolute measure of variance of the true effect sizes across studies), and p-value for Cochran’s Q test for residual heterogeneity were 73.9%, 0.2, and <0.001 for AUC, respectively and for the Mean Difference in Contrast they were 78.2%, 0.08, and <0.001, respectively.
Tomography 12 00065 g002
Figure 3. Funnel plots of AUC values (a) and Difference of Mean Differences (b) comparing LGG to HGG.
Figure 3. Funnel plots of AUC values (a) and Difference of Mean Differences (b) comparing LGG to HGG.
Tomography 12 00065 g003
Figure 4. Baujat plots to visualize the heterogeneity of each study on AUC [10,11,18,19,22,23,24,25,26,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57]. (a) and mean difference in contrast to comparing LGG to HGG (b). Hou et al. [23] 2024, Zou et al. [53] 2017, and Zhang et al. [51] 2018 were the main studies that had large Pearson residuals with large influence on the pooled AUC values, while Yegnaraman et al. [55] 2025, Park et al. [44] 2015b, Ying et al. [54] 2025, and Sakata et al. [46] 2018 were the main studies that had large Pearson residuals with large influence on the pooled mean difference of contrast.
Figure 4. Baujat plots to visualize the heterogeneity of each study on AUC [10,11,18,19,22,23,24,25,26,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57]. (a) and mean difference in contrast to comparing LGG to HGG (b). Hou et al. [23] 2024, Zou et al. [53] 2017, and Zhang et al. [51] 2018 were the main studies that had large Pearson residuals with large influence on the pooled AUC values, while Yegnaraman et al. [55] 2025, Park et al. [44] 2015b, Ying et al. [54] 2025, and Sakata et al. [46] 2018 were the main studies that had large Pearson residuals with large influence on the pooled mean difference of contrast.
Tomography 12 00065 g004
Table 1. Description of parameters affecting CEST MRI acquisition.
Table 1. Description of parameters affecting CEST MRI acquisition.
ParameterEffectDescription
SaturationB1 averageExchange Rate TuningAverage RF power during saturation increases sensitivity; increased B1,avg increases optimal exchange rate [15,28]
Duty Cycle (DC)Exchange Rate TuningProportion of time during which saturation is applied relative to the total saturation duration; reduced DC can suppress slow CEST compared to high DC [29,30,31,32]
CEST RF Saturation TimeExchange Rate Tuning/Steady-StateTotal Saturation Duration; fast-exchanging protons maximize sensitivity at shorter Tsat, while slower exchanges maximize sensitivity closer to steady state [28,33]
Image ReadoutRepetition TimeImage ReadoutTime between successive saturation–readout cycles; relaxation recovery and reproducibility of steady-state signal [34]
Dimension (2D/3D)Image ReadoutSequence dimensionality affects timing, resolution and Signal-to-Noise Ratio (SNR)
Echo (Gradient/Spin)Image ReadoutType of sequence echo can affect sensitivity or timing
Vendor (Scanner)Image ReadoutScanner vendor affects access to pre-installed sequences
Table 2. Characteristics of glioma grading using APTw MRI in selected studies.
Table 2. Characteristics of glioma grading using APTw MRI in selected studies.
AuthorsAUCCut-OffHGGLGGMean Diff.
nMeanSDnMeanSD
1. Zhou et al. [52] 20130.981.9282.50.5561.090.421.41
2. Park et al. [44] 2015b0.863.72641.2192.30.81.7
3. Park et al. [10] 2015a0.841.72302.91.6101.10.91.8
4. Sakata et al. [45] 20150.881.21181.350.4480.780.30.57
5. Togao et al. [19] 20160.892.56142.70.58201.870.490.83
6. Bai et al. [36] 20170.83NaN262.10.2181.30.20.8
7. Choi et al. [18] 20170.881.53312.210.88150.840.61.37
8. Sakata et al. [11] 20170.822.7211NaNNaN10NaNNaNNaN
9. Su et al. [49] 20170.792.93143.610.155282.640.180.97
10. Zou et al. [53] 20170.942.34262.770.35251.980.580.79
11. Chen et al. [37] 20180.72NaN134.52.372.91.11.6
12. Paech et al. [24] 20180.763.66253.961.3263.071.50.89
13. Sakata et al. [46] 20180.761.26341.330.46150.870.390.46
14. Zhang et al. [51] 20180.54NaN164.461.44164.232.060.23
15. Durmo et al. [39] 20200.902.38132.60.9791.490.51.11
16. Kang et al. [41] 20200.842.53183.91.292.061.551.84
17. Su et al. [47] 20200.742.14393.020.95302.270.850.75
18. Debnath et al. [38] 20210.793.6310NaNNaN14NaNNaNNaN
19. Su et al. [48] 2021a0.78NaN25NaNNaN39NaNNaNNaN
20. Su et al. [26] 2021b0.82NaN68NaNNaN45NaNNaNNaN
21. Xu et al. [25] 20210.91.55172.250.86131.040.481.21
22. Guo et al. [22] 20220.73NaN482.811.25142.150.80.66
23. Hou et al. [41] 20220.892.72483.270.65332.250.471.02
24. Liu et al. [43] 20220.72NaN232.860.72152.130.890.73
25. Zhang et al. [50] 20220.913.5215NaNNaN10NaNNaNNaN
26. Filimonova et al. [40] 20240.77NaN37NaNNaN5NaNNaNNaN
27. Hou et al. [23] 20240.932.38342.760.51241.840.470.92
28. Ying et al. [54] 20250.77NaN491.870.62231.460.490.41
29. Yegnaraman et al. [55] 20250.802.80373.300.86201.880.351.42
30. Takami et al. [56] 20250.99NaN192.91NaN60.44NaN2.47
31. Jiang et al. [57] 20250.83NaN832.900.82541.930.580.97
Table 3. Imaging parameters for APTw MRI used in selected studies.
Table 3. Imaging parameters for APTw MRI used in selected studies.
AuthorsReadout ParametersCEST Parameters
ScannerB0dim.ProtocolEchoTRB1TsatDCNp
1. Zhou et al. [52] 2013Philips33DGRASEBoth30.50.830.964
2. Park et al. [44] 2015bPhilips33DGREGRE0.140.420.0711
3. Park et al. [10] 2015aPhilips33DGREGRE0.140.420.0711
4. Sakata et al. [45] 2015Siemens33DGREGRENaN20.60.53
5. Togao et al. [19] 2016Philips32DFSESE522140
6. Bai et al. [36] 2017GE32DGREGRE3.2210.55
7. Choi et al. [18] 2017Philips33DEPISE320.814
8. Sakata et al. [11] 2017Toshiba32DFSESE910.830.9725
9. Su et al. [49] 2017GE3NaNNaNNaN320.411
10. Zou et al. [53] 2017Philips32DTSESE320.830.964
11. Chen et al. [37] 2018Siemens32DGREGRE1.341.60.515
12. Paech et al. [24] 2018Siemens72DGREGRENaN13.750.6150
13. Sakata et al. [46] 2018Siemens32DGREGRENaN20.60.53
14. Zhang et al. [51] 2018GE32DEPISE320.411
15. Durmo et al. [39] 2020Siemens33DGREGRENaN20.770.675
16. Kang et al. [41] 2020GE32DSESE320.411
17. Su et al. [47] 2020GE33DGREGRE320.613
18. Debnath et al. [38] 2021Philips3NaNNaNNaN320.814
19. Su et al. [48] 2021aGE32DGREGRE321.614
20. Su et al. [26] 2021bGE32DEPISE6.52211
21. Xu et al. [25] 2021GE32DGREGRE42214
22. Guo et al. [22] 2022Siemens348SPACESE32.51110
23. Hou et al. [41] 2022Philips33DFSESE5.932211
24. Liu et al. [43] 2022Philips3NaNNaNNaN320.814
25. Zhang et al. [50] 2022Philips3NaNNaNNaN6.3NaNNaNNaNNaN
26. Filimonova et al. [40] 2024Philips33DEPISE5.93NaNNaNNaNNaN
27. Hou et al. [23] 2024Philips33DTSESE5.932211
28. Ying et al. [54] 2025United Imaging32DFSESE20.75111
29. Yegnaraman et al. [55] 2025Philips33DTSESE6.3122140
30. Takami et al. [56] 2025GE32DFSESE3.032211
31. Jiang et al. [57] 2025Siemens33DSPACESE32.51.10.9110
Table 4. Missing values, I2, R2, τ2, and p-values of the omnibus test for examining univariate moderator effects of AUC comparing LGG vs. HGG.
Table 4. Missing values, I2, R2, τ2, and p-values of the omnibus test for examining univariate moderator effects of AUC comparing LGG vs. HGG.
Covariate NameMissing ValueI2 (%)R2 (%)τ2p-Value
Null *0 (12)73.9 (83.0)/0.202 (0.330)/
B0 **0 (12)74.9 (83.0)0.0 (/)0.211 (0.330)0.55 (/)
Dim. [3D]3 (12)73.9 (82.1)1.8 (0.0)0.208 (0.337)0.33 (0.56)
Echo [Spin Echo]4 (12)76.8 (83.5)0.0 (0.0)0.236 (0.358)0.75 (0.75)
TR4 (12)75.8 (82.9)2.4 (0.7)0.216 (0.327)0.26 (0.27)
B12 (12)75.7 (83.6)0.0 (0.0)0.218 (0.356)0.81 (0.81)
Tsat2 (12)74.2 (79.2)2.5 (4.8)0.202 (0.267)0.27 (0.04)
PC-related Meta-Regression Analyses
Exchange Rate Tuning2 (12)75.4 (83.2)0.0 (0.0)0.214 (0.341)0.56 (0.43)
Exchange Rate Tuning within 1 SD2 (12)75.8 (83.6)0.0 (0.0)0.218 (0.357)0.90 (0.93)
Read-out9 (12)80.2 (82.9)0.1 (0.2)0.263 (0.329)0.32 (0.25)
Read-out
within 1 SD
9 (12)79.6 (82.1)2.0 (4.6)0.258 (0.314)0.44 (0.34)
Steady State6 (12)76.1 (81.9)7.3 (6.8)0.212 (0.307)0.14 (0.14)
Steady State
within 1 SD
6 (12)75.0 (82.1)12.4 (4.6)0.201 (0.314)0.14 (0.34)
Total9 (12)80.6 (83.2)0.0 (0.0)0.272 (0.343)0.55 (0.67)
Total PC
within 1 SD
9 (12)79.7 (83.0)1.4 (1.0)0.260 (0.326)0.23 (0.23)
Protocol Time Shift (2015, 2021)0 (12)72.4 (82.6)5.4 (0.0)0.191 (0.342)0.23 (0.50)
Liberal analysis (maximum studies) is expressed with restricted analysis (no missing values) in parentheses. * The first row corresponds to the original meta-analysis without covariate adjustment. ** For B0, the moderator effect was not available using complete case analysis because all the included studies used the same B0 value.
Table 5. Missing values, I2, R2, τ2, and p-values of the omnibus test for examining univariate moderator effects of mean difference in contrast comparing LGG vs. HGG.
Table 5. Missing values, I2, R2, τ2, and p-values of the omnibus test for examining univariate moderator effects of mean difference in contrast comparing LGG vs. HGG.
Covariate NameMissing ValueI2 (%)R2 (%)τ2p-Value
Null *7 (13)78.2 (75.5)/0.079 (0.084)/
B0 **7 (13)79.2 (75.5)0.0 (/)0.080 (0.085)0.93 (/)
Dim. [3D]9 (13)74.1 (62.4)3.9 (39.0)0.09 (0.052)0.26 (0.031)
Echo [Spin Echo]9 (13)76.7 (73.3)0.0 (0.0)0.103 (0.093)0.89 (0.25)
TR11 (13)78.9 (77.9)0.0 (0.0)0.079 (0.099)0.70 (0.60)
B17 (13)79.3 (77.2)0.0 (0.0)0.084 (0.094)0.13 (0.20)
Tsat7 (13)78.0 (77.3)0.0 (0.0)0.085 (0.097)0.99 (0.51)
PC-related Meta-Regression Analyses
Exchange Rate Tuning7 (13)75.6 (75.4)1.3 (0.0)0.078 (0.092)0.066 (0.17)
Exchange Rate Tuning within 1 SD7 (13)77.4 (75.0)0.0 (0.0)0.089 (0.098)0.51 (0.79)
Read-out13 (13)76.6 (76.6)0.0 (0.0)0.0990.57 (0.57)
Read-out
within 1 SD
13 (13)68.9 (68.9)23.1 (23.1)0.065 (0.065)0.034 (0.034)
Steady State11 (13)78.4 (77.7)0.0 (0.0)0.079 (0.099)0.67 (0.56)
Steady State within 1 SD11 (13)72.5 (71.4)15.3 (12.9)0.057 (0.074)0.062 (0.094)
Total13 (13)67.1 (67.1)23.5 (23.5)0.065 (0.065)0.02 (0.02)
Total PC within 1 SD13 (13)71.1 (71.1)0.6 (0.6)0.084 (0.084)0.096 (0.096)
Protocol Time Shift (2015, 2021)7 (13)79.6 (72.7)0.0 (0.5)0.092 (0.084)0.50 (0.19)
Liberal analysis (maximum studies) is expressed with restricted analysis (no missing values) in parentheses. * The first row corresponds to the original meta-analysis without covariate adjustment. ** For B0, the moderator effect was not available using complete case analysis because all the included studies used the same B0 value.
Table 6. Summary table for leave-one-out meta-analysis (LOOMA) for AUC.
Table 6. Summary table for leave-one-out meta-analysis (LOOMA) for AUC.
Removed StudyAUCCI LowCI UpperQ-Valueτ2I2
Zhang et al. [51] 20180.820.790.8460.290.0851.07
Chen et al. [37] 20180.820.780.85147.980.2174.37
Liu et al. [43] 20220.820.780.85147.170.273.71
Guo et al. [22] 20220.820.780.85147.340.2173.57
Su et al. [47] 20200.820.780.85147.780.2173.46
Paech et al. [24] 20180.820.780.85148.790.2174.88
Sakata et al. [46] 20180.820.780.85148.750.2174.47
Filimonova et al. [40] 20240.820.780.85148.830.2174.97
Ying et al. [54] 20250.820.780.85148.830.2174.23
Su et al. [48] 2021a0.820.780.85148.760.2174.66
Debnath et al. [38] 20210.820.780.84148.730.2175.07
Su et al. 20170.820.780.84148.660.2175.02
Yegnaraman et al. [55] 20250.820.780.84148.110.2174.82
Sakata et al. [11] 20170.810.780.84148.310.2175
Su et al. [26] 2021b0.810.780.84145.590.2274.21
Bai et al. [36] 20170.810.780.84147.430.2174.9
Jiang et al. [57] 20250.810.780.84143.310.2173.93
Kang et al. [41] 20200.810.780.84147.560.2174.86
Park et al. 2015a0.810.780.84147.010.2174.81
Park et al. [44] 2015b0.810.780.84145.550.2174.46
Choi et al. [18] 20170.810.780.84144.30.274.06
Sakata et al. [45] 20150.810.780.84146.260.274.34
Hou et al. [41] 20220.810.780.84139.340.1973.03
Togao et al. [19] 20160.810.780.84145.790.274.17
Durmo et al. [39] 20200.810.780.84146.260.274.23
Xu et al. [25] 20210.810.780.84145.170.273.95
Zhang et al. [50] 20220.810.780.84145.420.273.96
Hou et al. [23] 20240.810.780.84139.280.1872.06
Zou et al. [53] 20170.810.780.84141.010.1872.55
Zhou et al. [52] 20130.810.780.84146.790.274.35
Takami et al. [56] 20250.810.780.84145.150.274.17
Table 7. Summary table for leave-one-out meta-analysis (LOOMA) for mean difference.
Table 7. Summary table for leave-one-out meta-analysis (LOOMA) for mean difference.
Removed StudyMean
Difference
CI LowCI UpperQ-Valueτ2I2
Zhang et al. [51] 20180.960.811.1174.240.0879.05
Ying et al. [54] 20250.980.841.1261.980.0673.82
Sakata et al. [46] 20180.980.831.1263.490.0774.89
Sakata et al. [45] 20150.970.821.1270.530.0877.68
Guo et al. [22] 20220.960.811.1174.660.0879.41
Liu et al. [43] 20220.960.811.11750.0879.59
Su et al. [47] 20200.960.811.1174.920.0879.61
Zou et al. [53] 20170.960.811.1274.770.0979.33
Bai et al. [36] 20170.960.811.1272.640.0976
Togao et al. [19] 20160.960.811.1175.240.0979.78
Paech et al. [24] 20180.950.81.175.340.0879.21
Hou et al. [23] 20240.960.81.1175.280.0979.55
Jiang et al. [57] 20250.950.81.1174.890.0979.36
Su et al. [49] 20170.950.81.1172.160.0975.43
Hou et al. [41] 20220.950.791.174.170.0979.29
Durmo et al. [39] 20200.950.81.174.850.0879.43
Xu et al. [25] 20210.940.791.0973.630.0878.99
Choi et al. [18] 20170.930.781.0770.540.0777.43
Zhou et al. [52] 20130.930.791.0871.250.0777.6
Yegnaraman et al. [55] 20250.920.781.0664.190.0674.77
Chen et al. [37] 20180.940.81.0974.470.0878.86
Park et al. 2015b0.920.781.0667.890.0775.43
Park et al. [10] 2015a0.930.791.0770.330.0777.01
Kang et al. [41] 20200.940.791.0872.730.0878.29
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Chung, J.J.; Ma, T.; Philbrook, P.; Zhou, T.; Goldman-Yassen, A.E.; Sun, P.Z. Quantitative Consistency of Amide Proton Transfer-Weighted MRI for Brain Tumor Differentiation: Systematic Review of Clinical Evidence. Tomography 2026, 12, 65. https://doi.org/10.3390/tomography12050065

AMA Style

Chung JJ, Ma T, Philbrook P, Zhou T, Goldman-Yassen AE, Sun PZ. Quantitative Consistency of Amide Proton Transfer-Weighted MRI for Brain Tumor Differentiation: Systematic Review of Clinical Evidence. Tomography. 2026; 12(5):65. https://doi.org/10.3390/tomography12050065

Chicago/Turabian Style

Chung, Julius Juhyun, Tianwen Ma, Phaethon Philbrook, Toby Zhou, Adam Ezra Goldman-Yassen, and Phillip Zhe Sun. 2026. "Quantitative Consistency of Amide Proton Transfer-Weighted MRI for Brain Tumor Differentiation: Systematic Review of Clinical Evidence" Tomography 12, no. 5: 65. https://doi.org/10.3390/tomography12050065

APA Style

Chung, J. J., Ma, T., Philbrook, P., Zhou, T., Goldman-Yassen, A. E., & Sun, P. Z. (2026). Quantitative Consistency of Amide Proton Transfer-Weighted MRI for Brain Tumor Differentiation: Systematic Review of Clinical Evidence. Tomography, 12(5), 65. https://doi.org/10.3390/tomography12050065

Article Metrics

Back to TopTop